NASDAQ:RADX - Nasdaq - ADR - Currency: USD
NASDAQ:RADX (5/2/2025, 8:19:05 PM)
4.15
+0.15 (+3.75%)
The current stock price of RADX is 4.15 USD. In the past month the price decreased by -11.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.18B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm has a pipeline of highly differentiated molecules spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including brain, lung, breast and pancreas. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
RADIOPHARM THERANOSTICS LTD
Level 3, 62 Lygon Street, Carlton
Melbourne VICTORIA AU
Employees: 0
Phone: 61398245254
The current stock price of RADX is 4.15 USD. The price increased by 3.75% in the last trading session.
The exchange symbol of RADIOPHARM THERANOSTICS LTD is RADX and it is listed on the Nasdaq exchange.
RADX stock is listed on the Nasdaq exchange.
6 analysts have analysed RADX and the average price target is 4.44 USD. This implies a price increase of 6.9% is expected in the next year compared to the current price of 4.15. Check the RADIOPHARM THERANOSTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
RADIOPHARM THERANOSTICS LTD (RADX) has a market capitalization of 32.29M USD. This makes RADX a Nano Cap stock.
RADIOPHARM THERANOSTICS LTD (RADX) currently has 0 employees.
RADIOPHARM THERANOSTICS LTD (RADX) has a support level at 3.88. Check the full technical report for a detailed analysis of RADX support and resistance levels.
The Revenue of RADIOPHARM THERANOSTICS LTD (RADX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the RADX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RADX does not pay a dividend.
RADIOPHARM THERANOSTICS LTD (RADX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.68).
The outstanding short interest for RADIOPHARM THERANOSTICS LTD (RADX) is 0.78% of its float. Check the ownership tab for more information on the RADX short interest.
ChartMill assigns a technical rating of 1 / 10 to RADX.
ChartMill assigns a fundamental rating of 3 / 10 to RADX. RADX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months RADX reported a non-GAAP Earnings per Share(EPS) of -9.68. The EPS increased by 52.2% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.34% | ||
ROE | -78.79% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to RADX. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 62.17% and a revenue growth -100% for RADX